The list of national drug standard substance collaborative calibration laboratories has been released

Multiple national standard products such as HLA and HPA, including Weihe, have participated in calibration

On September 15, 2021, the China Academy of Food and Drug Control issued a notice on updating the list of national drug standard substance collaborative calibration laboratories, which will update the current list of participating national drug standard substance collaborative calibration laboratories. Among the 196 national laboratories listed, Jiangsu Weihe Biotechnology Co., Ltd. stands out as one of the few Jiangsu enterprises with its deep cultivation and outstanding performance in the field of precise blood transfusion and transplantation molecular diagnosis.

As a representative of the supply of molecular diagnostic products, Weihe Biotechnology has assisted the China Food and Drug Control Research Institute in formulating multiple standards, including the national reference for human leukocyte antigen HLA-B27 nucleic acid testing and the national reference for HLA-B * 5801/5701/1502 nucleic acid testing. This is also the first time that the China Inspection Institute has released standard products for the above-mentioned products. In addition to the completed standard materials, Weihe Biotechnology is currently actively cooperating with the China Food and Drug Control Research Institute to implement the development project of human platelet specific antigen standard materials, contributing its own corporate strength to precise blood matching.
 
Despite being monopolized by imported products for a long time in the fields of precision blood transfusion, transplantation and matching, Weihe Biotechnology has been deeply involved in this professional field for many years. As one of the few production enterprises, it can also stand out when competing with high-precision and cutting-edge import leading enterprises. The inclusion of Weihe Biotechnology in the list of national standard product agreement laboratories this time is a great encouragement for domestic enterprises to conduct independent research, a full affirmation of Weihe Biotechnology's product innovation ability, a hardcore test of the accuracy of results, and a recognition of the company as an industry newcomer in molecular fields such as precision blood transfusion and transplantation matching.

Weihe Biotechnology will forge ahead and make unremitting efforts to completely replace import monopolies in the future, achieve localization of molecular products such as precision blood transfusion and transplantation, and provide more diverse and cost-effective product choices for colleagues.

Previous article： Ding! Ding! Ding! The Weihe Molecular Classroom is now giving a lecture

Next article： Ding! Ding! Ding! The Weihe Molecular Classroom is now giving a lecture